Simulect basiliximab and Zenapax daclizumab regulatory update

The U.K.'s NICE issued a final appraisal document on immunosuppressive therapy for renal transplantation that recommended use of NVS's Simulect and Zenapax from PDLI and ROCZ as part of a calcineurin inhibitor-based immunosuppressive regimen. NICE recommended the drugs for induction therapy in the prophylaxis of acute organ rejection in patients undergoing renal transplantation, and said the therapy with the lowest acquisition cost should be used.

NICE also said that in initial or maintenance immunosuppressive therapy, a doctors' choice between Prograf tacrolimus from Fujisawa and NVS's Neoral cyclosporine should be based on the relative importance of their side effect profiles for individual patients. ...